NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Reports First Patient Enrolled in DEBRA Trial Using MammaPrint
MammaPrint 70-gene signature to aid in evaluation of de-escalation of radiation therapy in Stage I, Hormone Sensitive, HER2-Negative breast cancer
Read MoreAgendiaยฎ Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michiganโs Dr. Erin Cobain
SWOG S2206 will use MammaPrintยฎ breast cancer recurrence test to examine response to immunotherapy in women with high-risk HR+ breast cancer.
Read MoreMammaPrintยฎ approved for Reimbursement in the Netherlands
The Dutch National Healthcare Institute (ZIN) has approved MammaPrintยฎ for inclusion in the Dutch National health insurance basic package with immediate effect.
Read More